Nouscom
  • Home
  • About
  • Technology
  • Pipeline
  • Investors
  • News
    • Grants
    • Meetings
    • Press Releases
    • Publications
  • Contact
Next-generation treatment for cancer Next-generation treatment for cancer Next-generation treatment for cancer Next-generation treatment for cancer
  • Home
  • About
  • Technology
  • Pipeline
  • Investors
  • News
    • Grants
    • Meetings
    • Press Releases
    • Publications
  • Contact

Archives

Author Archive for: "fabiocrognale"
Home » Archivi per fabiocrognale
0

Nouscom announces leading publication revealing an immune mechanism of action driving anti-tumor activity of adenovirus vectored vaccines and anti-PD1 immunotherapy

Research paper published in Science Translational Medicine by Nouscom and the Armenise-Harvard Laboratory of Immunoregulation at IIGM led by Luigia Pace describes how Nouscom’s adenoviral based [...]

READ MORE
0

Nouscom Announces Positive Phase 1 Data of NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Immunotherapy for the Treatment of dMMR/MSI-H Solid Tumors, at ASCO 2022

NOUS-209 in combination with pembrolizumab is safe, highly immunogenic, and associated with promising early and long-term clinical efficacy in 20 MSI-H GI patients BASEL, Switzerland – 6th June [...]

READ MORE
0

Nouscom to Present Full Phase 1 Data of NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Immunotherapy for the Treatment of dMMR/MSI-H Solid Tumors, at ASCO 2022

BASEL, Switzerland – 27th May 2022 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vectored immunotherapies, today announced that full [...]

READ MORE
0

Nouscom Announces Promotion of Richard Davis to Chief Operating Officer

BASEL, Switzerland –23rd May 2022 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vectored immunotherapies, today announced the promotion [...]

READ MORE
0

Nouscom Announces Janssen Receives US FDA IND Clearance for VAC85135, an ‘Off-The-Shelf’ Cancer Immunotherapy Developed using Nouscom’s Proprietary Viral Vector Platform

VAC85135 is a novel clinical candidate developed by Nouscom and Janssen under a multi-project agreement BASEL, Switzerland – 17th May 2022 – Nouscom, a clinical stage immuno-oncology [...]

READ MORE
0

Nouscom Announces New Translational Phase 1 Data of NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Vaccine for the Treatment of MSI-H Solid Tumors, at AACR 2022

BASEL, Switzerland – 11th April 2022 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vectored immunotherapies, today announced [...]

READ MORE
0

Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion

Nouscom recently published in the Journal for ImmunoTherapy of Cancer a manuscript entitled: “Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, [...]

READ MORE
0

Nouscom to present interim data from Phase 1 trial evaluating NOUS-209, an ‘off-the-shelf’ neoantigen cancer vaccine for the treatment of MSI-H solid tumors

Results presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting BASEL, Switzerland – 10th November 2021 – Nouscom, a clinical stage immuno-oncology company developing [...]

READ MORE
0

Nouscom AG: Abstract on interim results from Phase 1 trial for NOUS-209, an “off-the-shelf” neoantigen cancer vaccine, in MSI-H solid tumors will be presented at SITC

Our abstract “Phase 1 Interim Study Results of Nous-209, an Off-the-Shelf Immunotherapy, with Pembrolizumab, for the Treatment of Tumors with a Deficiency in Mismatch Repair/ Microsatellite [...]

READ MORE
0

Dr. Elisa Scarselli will join as Expert Speaker at the virtual Neoantigen Based Therapies Summit

Our Co-Founder and CSO Dr. Elisa Scarselli will join as Expert Speaker at the virtual Neoantigen Based Therapies Summit from October 26 – 28, 2021. Find out more about the conference and [...]

READ MORE
1 2 3 4 5 6 7
page 1 of 7
Contact
  • NOUSCOM
  • info@nouscom.com
  • nouscom.com
Our Privacy

Privacy Policy & Cookie Low

Nouscom is a private oncology company developing next generation immunotherapies, founded in 2015 by an experienced management team that has worked together for many years in previous successful enterprises. Nouscom’s proprietary technology platform harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.

© Copyright 2018 | Made with by
error: Content is protected !!!